Rapid decline in lung function in COPD is associated with decreased CD25brightFoxP3 regulatory T cells in BAL

Author(s):  
Jonas Eriksson Ström ◽  
Jamshid Pourazar ◽  
Robert Linder ◽  
Anders Blomberg ◽  
Anne Lindberg ◽  
...  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Jonas Eriksson Ström ◽  
Jamshid Pourazar ◽  
Robert Linder ◽  
Anders Blomberg ◽  
Anne Lindberg ◽  
...  

Abstract Background Differences in the expression of regulatory T cells (Tregs) have been suggested to explain why some smokers develop COPD and some do not. Upregulation of Tregs in response to smoking would restrain airway inflammation and thus the development of COPD; while the absense of such upregulation would over time lead to chronic inflammation and COPD. We hypothesized that—among COPD patients—the same mechanism would affect rate of decline in lung function; specifically, that a decreased expression of Tregs would be associated with a more rapid decline in FEV1. Methods Bronchoscopy with BAL was performed in 52 subjects recruited from the longitudinal OLIN COPD study; 12 with COPD and a rapid decline in lung function (loss of FEV1 ≥ 60 ml/year), 10 with COPD and a non-rapid decline in lung function (loss of FEV1 ≤ 30 ml/year), 15 current and ex-smokers and 15 non-smokers with normal lung function. BAL lymphocyte subsets were determined using flow cytometry. Results The proportions of Tregs with regulatory function (FoxP3+/CD4+CD25bright) were significantly lower in COPD subjects with a rapid decline in lung function compared to those with a non-rapid decline (p = 0.019). This result was confirmed in a mixed model regression analysis in which adjustments for inhaled corticosteroid usage, smoking, sex and age were evaluated. No significant difference was found between COPD subjects and smokers or non-smokers with normal lung function. Conclusions COPD subjects with a rapid decline in lung function had lower proportions of T cells with regulatory function in BAL fluid, suggesting that an inability to suppress the inflammatory response following smoking might lead to a more rapid decline in FEV1. Trial registration Clinicaltrials.gov identifier NCT02729220


2008 ◽  
Vol 27 (2) ◽  
pp. S179
Author(s):  
T. Nakagiri ◽  
G. Warnecke ◽  
M. Avsar ◽  
S. Thissen ◽  
B. Kruse ◽  
...  

PLoS ONE ◽  
2016 ◽  
Vol 11 (10) ◽  
pp. e0164751 ◽  
Author(s):  
Mahyar Ostadkarampour ◽  
Malin Müller ◽  
Johan Öckinger ◽  
Susanna Kullberg ◽  
Anders Lindén ◽  
...  

Surgery Today ◽  
2011 ◽  
Vol 42 (3) ◽  
pp. 250-258 ◽  
Author(s):  
Tomoyuki Nakagiri ◽  
Gregor Warnecke ◽  
Murat Avsar ◽  
Stefanie Thissen ◽  
Bianca Kruse ◽  
...  

Autoimmunity ◽  
2009 ◽  
pp. 1-1
Author(s):  
Jose Miguel Sempere-Ortells ◽  
Vicente Perez-Garcia ◽  
Gema Marin-Alberca ◽  
Alejandra Peris-Pertusa ◽  
Jose Miguel Benito ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document